

BOARD CHANGES

Melbourne, Australia, 29th September 2026: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics technology company, advises that Mr Gavin Fox-Smith has resigned as Chair and Non-Executive Director of the Company, effective immediately.

Mr Fox-Smith has advised the Board that, having regard to his other board commitments, he is no longer able to dedicate the time he believes the role requires, particularly as Rhythm progresses through the next phase of its commercialisation strategy. He remains strongly committed to Rhythm's purpose, highly supportive of the Company and its team, and a supportive shareholder.

The Board thanks Mr Fox-Smith for his leadership as Chair and his contribution to Rhythm and wishes him well with his other commitments.

Appointment of Interim Chair

The Board has appointed Ms Sue MacLeman, a Non-Executive Director of Rhythm since January 2023, as Interim Chair, effective immediately. Ms MacLeman has more than 30 years' experience across the pharmaceutical, biotechnology and medtech sectors and brings extensive commercial, corporate and governance experience to the role. The Board will consider longer-term Chair arrangements in due course and will update the market as appropriate.

Ms MacLeman said: "On behalf of the Board, I would like to thank Gavin for his contribution and leadership. Rhythm's strategy and commercial priorities are unchanged. The Board, including our recently appointed Directors, Maureen Baker and Carl Stubbings, will work closely with Managing Director and CEO Dr David Atkins and the executive team as the Company progresses its commercial objectives for ColoSTAT® and geneType™ in Australia and internationally."

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information please contact investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an innovative Australian medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with like-minded global partners to achieve

Rhythm Biosciences Ltd

ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address

Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors

Sue MacLeman
Maureen Baker
Carl Stubbings
David Atkins

Non-Executive Chair (Interim)
Non-Executive Director
Non-Executive Director
CEO & Managing Director

commercialisation and distribution of these simple solutions. The Company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Biosciences' simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with CRC. The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalised health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.